BioNTech SE (BNTX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about BioNTech SE (BNTX)
Go deeper and ask any question about BNTX
Company Performance
Current Price
as of Sep 13, 2024$123.40
P/E Ratio
N/A
Market Cap
$29.34B
Description
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Metrics
Overview
- HQMainz, RP
- SectorHealth Technology
- IndustryBiotechnology
- TickerBNTX
- Price$123.4+17.52%
Trading Information
- Market Cap$29.34B
- Float99.74%
- Average Daily Volume (1m)1,129,467
- Average Daily Volume (3m)825,828
- EPS-$2.28
Company
- Revenue$2.91B
- Rev Growth (1yr)-24.09%
- Net Income-$869.63M
- Gross Margin53.54%
- EBITDA Margin-504.74%
- EBITDA-$699.32M
- EV$8.26B
- EV/Revenue2.84
- P/EN/A
- P/S10.09
Documents
Factset Street Account
Earnings Calls
Factset